Perimeter Launches OCT-Tissue Registry to Power AI and Imaging Innovation
"I have used Perimeter's OCT technology in more than 120 surgeries, and it has become an invaluable tool," said Dr. Jennifer Tittensor, a general surgeon for Timpanogos Regional Hospital and the first contributor to the OCT-Tissue Registry. "In my practice, it helps me assess margins in real-time and decide whether I need to remove more tissue - potentially avoiding the need for a second surgery. Being a part of the registry allows me to track and analyze patient outcomes and help shape future improvements in the technology. I am excited to be involved."
Perimeter's S-Series OCT utilizes the company's patented wide-field optical coherence tomography ("OCT") technology to enable surgeons to visualize tissue specimens in real-time, with ultra-high resolution, during surgery. Building on this foundation, the investigational next-generation B-Series OCT with ImgAssist AI 2.0, under premarket approval review by the U.S. Food and Drug Administration, integrates AI and is intended to help surgeons more efficiently detect suspicious tissue during breast-conserving surgery.
"The launch of this registry provides an opportunity to patients and surgeons to help future patients have better clinical care," said Perimeter CEO Adrian Mendes. "We look forward to collaborating with physicians to collect high-quality data and images from a broad and diverse patient population. The more images we can gather from the widest range of patients, the better we can train our AI algorithm to detect patterns in various tissue types. This registry could potentially help physicians provide more personalized care, achieve clean margins more frequently, and reduce the need for second surgeries due to residual cancer."
One of the biggest challenges with developing non-generative AI for medical applications is acquiring a large, diverse dataset that reflects a full range of patient characteristics, such as age, ethnicity, tissue density, and body mass. To develop the ImgAssist AI algorithm, Perimeter trained its deep learning models using several million proprietary OCT images of cancerous and healthy tissue. These models, created by the company's AI team, were designed for real-time use.
The launch of the OCT-Tissue Registry enables Perimeter to use real-world images and clinical data to make its AI model even more sophisticated. The registry also allows surgeons to contribute retrospective data and track patient outcomes to evaluate surgical results over time.
To learn more or inquire about participation in OCT-Tissue Registry, please contact Perimeter Medical Imaging AI Clinical Affairs at [email protected].
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. Patient enrollment completed in September 2024, with expected FDA submission in 2025. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.
S-Series Intended Use
The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest.
S-Series Unapproved Uses
The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. Clinical evidence related to these uses can be found in the clinical evidence listed below. Contraindications, limitations, warnings and precautions, and how to obtain a full copy of the FDA-required instructions for use are also provided on this page.
For more information on unapproved/off-label uses, contact [email protected].
B-Series Intended Use
B-Series OCT is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. The device is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
CAUTION: Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. The safety and effectiveness of this device has not yet been evaluated by the U.S. FDA. For more information, please contact [email protected].
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the PMA submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: [email protected]
Susan Thomas
Media Relations
Direct: 619-540-9195
Email: [email protected]
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: [email protected]
SOURCE Perimeter Medical Imaging AI Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
Lotto Max - The $70 million jackpot was won in Québec Français
MONTRÉAL, July 12, 2025 /CNW/ - Last night's $70 million Lotto Max jackpot was won by the holders of 2 selections sold in Québec. The holders of these winning selections each won $35 million "This is the second time in a couple of weeks that the Lotto Max jackpot has been won here. What luck for Quebecers!" points out Isabelle Jean, Executive Vice-President and Chief Operating Officer of Lottery Games at Loto-Québec. The next Lotto Max draw will be held on Tuesday, July 15 and will offer an estimated $19 million jackpot. Draw results are available online at About Loto-Québec Loto-Québec has been delivering entertainment to Quebecers for over 50 years, and its operations benefit Québec as a whole. Last year, the corporation paid out almost $1.8 billion in prizes to winners across Québec. Major prize winners are listed on the Winners page in the Lotteries section of Read their stories. The responsible commercialization of lottery and gaming products is central to Loto-Québec's operations. The corporation has been granted the highest internationally recognized certification in responsible gaming by the World Lottery Association.
Cision Canada
8 hours ago
- Cision Canada
Graphene Manufacturing Group Ltd. Announces Agreement for At-The-Market Offering
BRISBANE, Australia, /CNW/ - Graphene Manufacturing Group Ltd. (TSXV: GMG) OTCQX: GMGMF) (" GMG" or the " Company") is pleased to announce that it has entered into an equity distribution agreement dated July 11, 2025 (the " Distribution Agreement") with Cantor Fitzgerald Canada Corporation (the " Agent"). Pursuant to the Distribution Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the Distribution Agreement, to sell, through the Agent, such number of ordinary shares of the Company (the " Ordinary Shares") that would result in aggregate gross proceeds to the Company of up to C$20 million (the " Offering" or " ATM Facility"). Sales of the Ordinary Shares, if any, will be made in "at the market distributions", as defined in National Instrument 44-102 – Shelf Distributions, directly on the TSX Venture Exchange (the " TSXV") or on any other existing trading market in Canada. No offers or sales of Ordinary Shares will be made on any exchange or quotation system outside of Canada. The Company will pay the Agent a fee equal to 3.0% of the gross proceeds from any sales of Ordinary Shares under the Offering as compensation for its services in acting as agent in connection with the sale of Ordinary Shares pursuant to the terms of the Distribution Agreement. Net proceeds from the ATM Facility, if any, will be used to fund ongoing operations including, but not limited to, commercial development, product development and working capital. The ATM Facility will be effective until the earlier of (i) the issuance and sale of an aggregate amount of C$20,000,000 of Ordinary Shares through the Agent; and (ii) April 10, 2027, unless earlier terminated prior to such date by the Company or the Agent. The Offering will be made by way of a prospectus supplement dated July 11, 2025 (the " Prospectus Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 filed with the securities regulatory authorities in each of the provinces and territories of Canada (together with the Prospectus Supplement, the " Offering Documents"). The Prospectus Supplement will be filed with each of the provincial securities commissions in Canada. The Offering Documents will contain important detailed information about the securities being offered. Before you invest, you should read the Offering Documents and the documents incorporated therein for more complete information about the Company and the Offering. Copies of the Distribution Agreement and the Offering Documents will be available for free by visiting the Company's profile on SEDAR+ at An electronic or paper copy of the Prospectus Supplement, the corresponding base shelf prospectus and any amendment to the documents may be obtained, without charge, from Cantor Fitzgerald Canada Corporation, 181 University Ave, Suite 1500, Toronto, ON M5H 3M7 or by telephone at (416)-350-1203 by providing the contact with an email address or address, as applicable. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or under any U.S. state securities laws, and may not be offered, sold, directly or indirectly, or delivered within the "United States" or to, or for the account or benefit of, persons in the "United States" or "U.S. persons" (as such terms are defined in Regulation S under the U.S. Securities Act) except in certain transactions exempt from the registration requirements of the U.S. Securities Act and all applicable U.S. state securities laws. About GMG: GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications. The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning (" HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines. In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries (" G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries. GMG's 4 critical business objectives are: Produce Graphene and Improve/Scale Cell Production Processes Build Revenue from Energy Savings Products Develop Next-Generation Battery Develop Supply Chain, Partners & Project Execution Capability Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the Company's proposed business plans, expectations regarding the sale of Ordinary Shares under the ATM Facility, the proceeds from the ATM Facility, and the Company's proposed use of the proceeds from the ATM Facility. Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the ATM Facility; use the proceeds from the ATM Facility as anticipated; the Company's performance and general business and economic conditions. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the ATM Facility as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the ATM Facility; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. SOURCE Graphene Manufacturing Group Ltd.
Globe and Mail
9 hours ago
- Globe and Mail
Galway Metals Announces Final Option Payment for Royalty Buy Back at Its Clarence Stream Property
TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Galway Metals Inc. (TSXV: GWM) (' Galway ' or the " Company") is pleased to announce that it intends to settle the sixth (6 th) and final of six (6) payments (the ' Sixth Partial Payment ') due in consideration of an agreement previously announced on July 21, 2020 (the ' Agreement ') by the cash payment of $125,000 and the issuance of 974,026 common shares in the Capital of the Company (' Shares ') at a deemed price equal to $0.385 per Share for a total deemed price of $375,000. Pursuant to the Agreement, the Company bought back a two percent (2.0%) net smelter returns royalty (the ' Royalty ') from an arm's length third party royalty holder (the ' Former Royalty Holder'), covering certain mineral claims at the Company's Clarence Stream property in southwest New Brunswick (the ' Property '). The Agreement provided for a total purchase price of $3,000,000 in six equal annual instalments of $500,000, with each partial payment representing the purchase of one-sixth (1/6) of the Royalty (each a ' Partial Payment '). The first Partial Payment was settled on Closing in 2020 through the issuance of 434,783 Shares to the Former Royalty Holder at a deemed price equal to $1.15 per Share for a total deemed price of $500,000. Pursuant to the Agreement, each subsequent $500,000 Partial Payment was to be paid as follows: (i) $125,000 in cash; and, (ii) the remaining $375,000, at the sole election of the Company, paid either in cash, through the issuance of Shares, or a combination thereof as shall equal $375,000. The Shares will be subject to the statutory hold periods of four months and one day from the date of issuance. Completion of the issuance of the Shares is subject to the receipt of all regulatory approval including the final approval of the TSXV. About Galway Metals Inc. Galway Metals is focused on creating significant per share value through the exploration and sustainable development of its two 100%-owned projects in Canada. Galway's flagship project, Clarence Stream, is one of the most important gold districts in Atlantic Canada as it hosts a large, high-grade gold resource in SW New Brunswick. Also important is Estrades, the former- producing, high-grade, gold- and zinc-rich polymetallic VMS mine in the northern Abitibi of western Quebec as it hosts significant resources in the middle of a major gold camp. After its successful spinout to existing shareholders from Galway Resources following the completion of the US$340 million sale of that company. The company is looking to replicate the same success in Canada with our two highly perspective projects. Should you have any questions and for further information, please contact (toll free): Cautionary Statement Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release. This News Release includes certain "forward-looking statements" which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'believes', 'anticipates', 'expects', 'estimates', 'may', 'could', 'would', 'will', or 'plan'. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, completion of the Royalty buy back on the announced terms or at all, objectives, goals or future plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to the risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
